These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2502156)

  • 41. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.
    Tóth FD; Szabó B; Ujhelyi E; Pálóczi K; Horváth A; Füst G; Kiss J; Bánhegyi D; Hollán SR
    AIDS; 1991 Mar; 5(3):263-8. PubMed ID: 1676275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Dynamics of the antibody response and p24 antigenemia in HIV-1 infected individuals in Czechoslovakia].
    Kopecká D; Brůcková M; Stanková M; Syrůcek L; Vojtĕchovský K; Petkov V
    Cesk Epidemiol Mikrobiol Imunol; 1990 Mar; 39(2):65-73. PubMed ID: 2142624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Immunochemical homology of HIV-1 envelope proteins and human apolipoprotein AI].
    Panin LE; Kostina NE; Poteriaeva ON; Fediuk NV
    Vopr Virusol; 2001; 46(5):13-6. PubMed ID: 11715702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease.
    Füst G; Tóth FD; Kiss J; Ujhelyi E; Nagy I; Bánhegyi D
    AIDS; 1994 May; 8(5):603-9. PubMed ID: 7914732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans.
    Haist S; März J; Wolf H; Modrow S
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1909-17. PubMed ID: 1489579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential IgG subclass responses to epitopes in transmembrane protein of HIV-1.
    Klasse PJ; Blomberg J; Pipkorn R
    Viral Immunol; 1990; 3(2):89-98. PubMed ID: 1694431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human immunodeficiency virus type 1 Brazilian subtype B variant showed an increasing avidity of the anti-V3 antibodies over time compared to the subtype B US/European strain in São Paulo, Brazil.
    Casseb J; Montanheiro P; Komninakis S; Brito A; Duarte AJ
    Mem Inst Oswaldo Cruz; 2004 Feb; 99(1):69-71. PubMed ID: 15057350
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [HIV antibody reaction caused by poliovirus].
    Fortschr Med; 1989 Jul; 107(22):12-3. PubMed ID: 2793021
    [No Abstract]   [Full Text] [Related]  

  • 49. [More and more of HIV non-B infections in Germany, too].
    Apel B
    Dtsch Med Wochenschr; 1997 Oct; 122(40):A9. PubMed ID: 9378042
    [No Abstract]   [Full Text] [Related]  

  • 50. Candidate AIDS vaccines.
    Graham BS; Wright PF
    N Engl J Med; 1995 Nov; 333(20):1331-9. PubMed ID: 7566026
    [No Abstract]   [Full Text] [Related]  

  • 51. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses.
    Nyambi PN; Nkengasong J; Peeters M; Simon F; Eberle J; Janssens W; Fransen K; Willems B; Vereecken K; Heyndrickx L
    J Infect Dis; 1995 Nov; 172(5):1228-37. PubMed ID: 7594658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
    Purtscher M; Trkola A; Gruber G; Buchacher A; Predl R; Steindl F; Tauer C; Berger R; Barrett N; Jungbauer A
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1651-8. PubMed ID: 7888224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children.
    Broliden K; Sievers E; Tovo PA; Moschese V; Scarlatti G; Broliden PA; Fundaro C; Rossi P
    Clin Exp Immunol; 1993 Jul; 93(1):56-64. PubMed ID: 8324904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV type 1 coreceptors, neutralization serotypes, and vaccine development.
    Moore J; Trkola A
    AIDS Res Hum Retroviruses; 1997 Jun; 13(9):733-6. PubMed ID: 9171216
    [No Abstract]   [Full Text] [Related]  

  • 55. Molecular mechanisms of immunoglobulin A defense.
    Childers NK; Bruce MG; McGhee JR
    Annu Rev Microbiol; 1989; 43():503-36. PubMed ID: 2508540
    [No Abstract]   [Full Text] [Related]  

  • 56. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I.
    Böttiger B; Ljunggren K; Karlsson A; Krohn K; Fenyö EM; Jondal M; Biberfeld G
    Clin Exp Immunol; 1988 Sep; 73(3):339-42. PubMed ID: 3208445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women.
    Battle-Miller K; Eby CA; Landay AL; Cohen MH; Sha BE; Baum LL
    J Infect Dis; 2002 Feb; 185(4):439-47. PubMed ID: 11865395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunology in AIDS in 1990.
    Sela M
    AIDS; 1990; 4 Suppl 1():S9-14. PubMed ID: 1983804
    [No Abstract]   [Full Text] [Related]  

  • 60. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.
    Kozlowski PA; Chen D; Eldridge JH; Jackson S
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):813-22. PubMed ID: 7986587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.